In a preliminary study, the group reported high accuracy for the detection of breast cancer within an hour by combining a fluorescence flow cytometer with fine-needle biopsies.
The company also said that preliminary full-year 2019 revenues are expected to be up 6 percent, with sample-to-answer revenues up more than 20 percent.
Called the "Ccheck Prostate Cancer Confirmation" test, Anixa's assay integrates flow cytometry and machine learning to identify evidence of cancer in a person's bloodstream.
Cytek said that the approval places the company on a path to offering a complete spectral flow cytometry solution — including instruments and reagents — to customers in China.
Rutgers researchers have developed a point-of-care tool that can rapidly assess the sensitivity of tumor cells to cancer drugs without staining or labeling.
